K1034 HCPCS Reimbursement & Policy Benchmarks

HCPCS Level II code K1034 denotes the provision of a nonprescription, self-administered and self-collected COVID-19 test that is FDA approved, authorized, or cleared, counted per individual test. Nationally, this code reflects payer and provider activity around over-the-counter at-home testing access and coverage, supporting public health testing capacity outside clinical settings. Coverage and billing of OTC COVID-19 tests affect consumer access, supply distribution, and claims processing workflows across commercial insurers and Medicare.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the code’s clinical context and use cases, typical sites of service, and the common operational and billing considerations tied to at-home OTC test distribution and reimbursement. The publication covers standard benchmarks for how this service is categorized, relevant payment application scenarios, and policy updates that influence how payers and providers process claims for self-administered COVID-19 tests. Where specific payer policies or contractual procedures vary, the report notes that those details are payer-determined. Data not available in the input is identified and omitted from the discussion.

Billing Code Overview

HCPCS Level II code K1034 describes the provision of a COVID-19 test that is nonprescription, self-administered and self-collected, and is FDA approved, authorized, or cleared, with a unit defined as one test count. The service type is over-the-counter (OTC) SARS-CoV-2 antigen or molecular testing for self-use, furnished directly to an individual for at-home use without a prescription. The typical site of service is the patient's residence or other non-clinical setting where the individual self-collects and performs the test.

Clinical Context

A patient requests a self-administered, nonprescription COVID-19 antigen or molecular test for travel, workplace screening, or symptom assessment. The patient is provided a single FDA-authorized over-the-counter, self-collection kit (K1034) at a clinic front desk, pharmacy counter, public health distribution point, or drive-through testing site. The typical workflow: patient arrival and brief eligibility check, verification of identity and counseling on test use (brief verbal instructions or printed instructions included with the kit), documentation of kit lot number and quantity dispensed in the medical record or inventory system, and issuance of one K1034 unit with education about manufacturer instructions for specimen collection, test performance, result interpretation, and disposal. No provider-performed specimen collection or laboratory processing is performed under this code; the patient self-collects and self-tests at home or on site per FDA authorization. Billing occurs for the physical provision of the OTC self-test device (one test count).

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	Use when additional work beyond typical dispensing occurs (rare for OTC kit provision) when documentation supports substantial additional effort.

Taxonomy Code	Specialty	Notes
`207Q00000X`	Family Medicine	Common setting for distribution at ambulatory clinics and primary care offices.
`207R00000X`	Internal Medicine	Kits provided to adult patients for home testing or screening.
`208D00000X`	Emergency Medicine	Distribution at ED or urgent care for discharge testing or take-home screening.
`363L00000X`	Pharmacy	Community pharmacists frequently provide OTC COVID-19 test kits and counseling.
`263Q00000X`	Public Health	Health department distribution sites and mass testing events providing self-test kits.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`Z20.828`	Contact with and (suspected) exposure to other viral communicable diseases	Used when patient seeks testing after known exposure and receives an OTC self-test kit.
`R05`	Cough	Symptom prompting use of a COVID-19 self-test kit for symptom assessment.
`R50.9`	Fever, unspecified	Common symptom leading patients to obtain an OTC COVID-19 test.
`Z11.59`	Encounter for screening for other viral diseases	Used for asymptomatic screening scenarios when a self-test kit is issued.
`U07.1`	COVID-19	Used when confirming or documenting a COVID-19 diagnosis; relevant if the OTC test result is subsequently reported and a diagnosis is established.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`99211`	Office or other outpatient visit for the evaluation and management of an established patient that may not require the presence of a physician	May be billed when minimal staff counseling or verification accompanies distribution of the OTC test kit in an office visit.
`99212`	Office or other outpatient visit for the evaluation and management of an established patient, low complexity	May accompany kit provision when brief clinician assessment and instruction are documented.
`99000`	Handling and/or conveyance of specimen for transfer from patient to laboratory (when used)	May be relevant if the patient self-collects a specimen that is then submitted to a lab (note: `K1034` describes self-test OTC kits, not lab-submitted specimens).
`87426`	Infectious agent antigen detection by immunoassay, multiple-step method; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	Relevant when lab-based antigen testing is performed instead of OTC self-test; often part of the alternative testing workflow.
`87635`	Infectious agent detection by nucleic acid (DNA or RNA); SARS-CoV-2, amplified probe technique	Relevant for laboratory molecular testing performed when confirmatory testing is required after a positive OTC self-test.

OpenPayer

Summary & Overview

HCPCS Level II K1034: COVID-19 Nonprescription Self-Administered OTC Test